2023年6月11日

ElevateBio——一個技術驅動的公司專注於推動創造生活的細胞和基因療法——最近宣布關閉其4.01億美元D係列融資由AyurMaya資本管理基金,由矩陣管理資本管理,加入了一個新的和現有投資者的領導小組。ElevateBio財團現在包括新投資者Woodline,李氏家族辦公室(亞洲),諾和諾德公司和研發夥伴,和現有的投資者:矩陣Capital Management, Invus集團愛默生集體,軟銀願景基金2,忠誠管理&研究公司,MPM資本,F2, Redmile集團EcoR1資本,輪回BioCapital,測量員資本(Citadel公司),EDBI,頂點企業,伊藤忠,大型機構投資者。與融資,哈利勒接二連三,Invus集團的董事總經理,被任命為ElevateBio的董事會。所得資金將用於進一步推進公司的技術平台——生命基因編輯,編輯誘導多能幹細胞(萬能)和RNA,細胞,蛋白質,向量工程BaseCamp,端到端遺傳醫學當前良好生產規範(cGMP)生產和過程開發業務,加快設計、製造、開發的細胞和基因療法。和資金還將支持ElevateBio繼續努力擴大它的地理範圍和增加其cGMP製造能力為其學術和工業合作夥伴提供交鑰匙和可伸縮的訪問技術和服務在整個產品生命周期。與諾和諾德公司在D係列的投資融資,ElevateBio整合子公司生活編輯療法還宣布了一項多目標與諾和諾德公司發現和開發基地合作編輯療法。隨著股權投資,生活編輯將收到預付一筆現金付款和有資格獲得潛在的發展,監管和商業裏程碑的250 - 3.35億美元以下七個項目的合作。生活編輯也有一個選項來選擇一個全球利潤分享計劃。這種合作強調ElevateBio形成新的產業的戰略合作關係,公司的技術基礎,而選擇性地促進自己的基因藥物的組合。自2021年前一輪融資,ElevateBio增壓其通過收購基因編輯功能,集成、生活和成長的小說編輯RGN和基礎編輯技術,導致多個合作夥伴,包括最近宣布與現代化療法和諾和諾德公司的合作。 And ElevateBio has also expanded access to its iPSC platform technology through a partnership with the California Institute for Regenerative Medicine and the formation of a new company aimed at developing iPSC-derived allogeneic immune cell therapies. The company has also increased BaseCamp manufacturing and process development capabilities to support a growing number of cell and gene therapy innovators. KEY QUOTES: “We have made significant strides in scaling our technologies and end-to-end capabilities in our pursuit to become the world’s most indispensable cell and gene therapy technology company. We are thrilled to welcome Khalil to our Board as his expertise will be invaluable as the number of strategic partners harnessing the power of our integrated ecosystem continues to grow. We’re emboldened by the pace of advancements to our technology platforms and continue to drive innovation from concept through commercialization and redefine how companies operate, how products are created, and how disease is treated.” — David Hallal, Chairman and Chief Executive Officer of ElevateBio “ElevateBio has created a truly disruptive business model with integrated technologies, capabilities, and capacity for which we see accelerating need as the complexity of cell and gene therapies continues to grow. In this still-nascent industry, we believe ElevateBio is looking several steps ahead to pave the path for partners across the biopharmaceutical industry to accelerate innovation and bridge the gap between discovery and widespread delivery of cell and gene therapies as everyday medicine.” — Khalil Barrage, Managing Director at The Invus Group Trending on Pulse 2.0